Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

Researchers discover promising new approach for leukemia treatment

A group of researchers at the Institute for Research in Immunology and Cancer of Universit- de Montr-al discovered a promising new approach to treating leukemia by disarming a gene that is responsible for tumor progression. That gene, known as Brg1 is a key regulator of leukemia stem cells that are the root cause of the disease, resistance to treatment and relapse.

13 Feb 2014

FDA grants full approval of SYNRIBO for injection

Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has granted full approval of SYNRIBO (omacetaxine mepesuccinate) for injection. This oncology portfolio product received an accelerated approval in October, 2012 with additional clinical trial data required to fulfill post marketing requirements set forth by the FDA.

13 Feb 2014

Researchers discover pre-leukemic stem cell that triggers relapse in patients with AML

Cancer researchers led by stem cell scientist Dr. John Dick have discovered a pre-leukemic stem cell that may be the first step in initiating disease and also the culprit that evades therapy and triggers relapse in patients with acute myeloid leukemia (AML).

13 Feb 2014

Cogstate technology to be applied in paediatric clinical trial in the U.S.

Medical technology company Cogstate Limited has today announced its technology will be used in a large paediatric clinical trial in the United States.

12 Feb 2014

Protein plays previously unknown role in acute myeloid leukemia development

There are potentially effective treatments for acute myeloid leukemia (AML), but they only work in 20 to 40 percent of cases. In a paper published today in Leukemia, a Nature journal, a UT Health Science Center researcher has pinpointed a protein that could play a key, previously unknown role in the development of pediatric AML - promising new information in the quest to treat and cure childhood leukemias.

12 Feb 2014

Combination of SYK and FLT3 enzymes promotes progression of acute myelogenous leukemia

Reinforcing the need to look beyond genomic alterations to understand the complexity of cancer, researchers from Dana-Farber/Boston Children's Cancer and Blood Disorders Center report that a normal enzyme called SYK pairs with FLT3, the most commonly mutated enzyme found in acute myelogenous leukemia (AML), to promote progression of the disease.

11 Feb 2014

Study points to molecular pathway to treat recurring, deadly malignancies

Analyzing the genomes of twin 3-year-old sisters – one healthy and one with aggressive leukemia – led an international team of researchers to identify a novel molecular target that could become a way to treat recurring and deadly malignancies.

9 Feb 2014

Researcher receives grant to find compounds that interrupt binding of cancer cells to blood vessels

In scary movies, the killer often comes back to life mysteriously, attacking again when the main character least expects it. Blood cancers are like this too, finding a safe spot to hide during treatment and then striking again when a patient is in remission.

7 Feb 2014

Chemical "signature" in blood may predict which AML patients would benefit from chemotherapy

Researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center have found a chemical "signature" in blood-forming stem cells that predicts whether patients with acute myeloid leukemia (AML) will respond to chemotherapy.

4 Feb 2014

Researchers identify protein critical to hematopoietic stem cell function, blood formation

Researchers at the University of California, San Diego School of Medicine have identified a protein critical to hematopoietic stem cell function and blood formation. The finding has potential as a new target for treating leukemia because cancer stem cells rely upon the same protein to regulate and sustain their growth.

3 Feb 2014

New study reveals way to combat drug-resistant tumors

Cancer drugs that recruit antibodies from the body's own immune system to help kill tumors have shown much promise in treating several types of cancer. However, after initial success, the tumors often return.

31 Jan 2014

AbbVie's global sales reduce 1.8% to $5.111B in fourth quarter 2013

AbbVie today announced financial results for the fourth quarter and full year ended Dec. 31, 2013.

31 Jan 2014

NeoGenomics validates and launches series of NeoTYPE cancer profiling tests

NeoGenomics, Inc., a leading provider of cancer-focused genetic and molecular testing services, announced today that it has validated and launched a series of NeoTYPE cancer profiling tests covering 22 different categories of cancer. Each of these tests is designed to investigate the most common and actionable genomic abnormalities reported for that particular tumor.

30 Jan 2014

CTI announces initiation of pacritinib Phase 2 trial in AML patients with FLT3 mutations

Cell Therapeutics, Inc. today announced the initiation of an international cooperative group Phase 2 clinical trial of pacritinib in adult patients with relapsed acute myeloid leukemia (AML) with mutations of the FLT3 gene. Mutation of the FLT3 gene is found in approximately one-third of AML patients and is an independent risk factor for poor prognosis.

30 Jan 2014

New pre-clinical data shows potential protective effects of GFT505 in different types of cancer

GENFIT, a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces new pre-clinical data demonstrating the inhibitory effects of GFT505 on the proliferation of cancer cells of different origins.

30 Jan 2014

TCGA Research Network identify new potential therapeutic targets for major form of bladder cancer

Investigators with The Cancer Genome Atlas (TCGA) Research Network have identified new potential therapeutic targets for a major form of bladder cancer, including important genes and pathways that are disrupted in the disease.

30 Jan 2014

High doses of 4-MEI in carbonated beverages may result in higher incidence of leukemia, says study

Last week, Consumer Reports released a study on the levels of a caramel coloring agent known as 4-methylimidazole (4-MEI) in many popular, carbonated beverages.

30 Jan 2014

Scientists develop monoclonal antibodies that may lead to new, innovative treatments for cancer patients

Using monoclonal antibodies to fight cancer is a complex, yet promising area of study. At Memorial Sloan Kettering Cancer Center, physician-scientists have focused their attention on expanding the current therapeutic antibody repertoire, and believe a newly developed platform will do just that - ultimately leading to new and innovative treatments for cancer patients with a broad range of malignancies.

29 Jan 2014

Transgenic mouse model validates mutant IDH2 protein as candidate for targeted anticancer therapies

In recent years, mutations in two metabolic enzymes, isocitrate dehydrogenase-1 and 2 (IDH1 and IDH2), have been identified in approximately 20 percent of all acute myeloid leukemias (AML). As a result, mutant IDH proteins have been proposed as attractive drug targets for this common form of adult leukemia.

29 Jan 2014

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Bristol-Myers Squibb Company today reported results for the fourth quarter and full year of 2013. The fourth quarter was highlighted by the company's announcement to sell its diabetes business as part of the continued evolution of its successful BioPharma strategy to a specialty care model. The company achieved important regulatory milestones in the quarter for Eliquis in the U.S., daclatasvir/asunaprevir in Japan, daclatasvir in Europe and Farxiga in the U.S. In addition, the company provided financial guidance for 2014.

24 Jan 2014

Leukemia News and Research

Further Reading

Researchers discover promising new approach for leukemia treatment

FDA grants full approval of SYNRIBO for injection

Researchers discover pre-leukemic stem cell that triggers relapse in patients with AML

Cogstate technology to be applied in paediatric clinical trial in the U.S.

Protein plays previously unknown role in acute myeloid leukemia development

Combination of SYK and FLT3 enzymes promotes progression of acute myelogenous leukemia

Study points to molecular pathway to treat recurring, deadly malignancies

Researcher receives grant to find compounds that interrupt binding of cancer cells to blood vessels

Chemical "signature" in blood may predict which AML patients would benefit from chemotherapy

Researchers identify protein critical to hematopoietic stem cell function, blood formation

New study reveals way to combat drug-resistant tumors

AbbVie's global sales reduce 1.8% to $5.111B in fourth quarter 2013

NeoGenomics validates and launches series of NeoTYPE cancer profiling tests

CTI announces initiation of pacritinib Phase 2 trial in AML patients with FLT3 mutations

New pre-clinical data shows potential protective effects of GFT505 in different types of cancer

TCGA Research Network identify new potential therapeutic targets for major form of bladder cancer

High doses of 4-MEI in carbonated beverages may result in higher incidence of leukemia, says study

Scientists develop monoclonal antibodies that may lead to new, innovative treatments for cancer patients

Transgenic mouse model validates mutant IDH2 protein as candidate for targeted anticancer therapies

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News